Received by email:

File: Imagin - News Release - Private Placement Closes - FINAL.docx


 
 
 CSE Symbol: IME
OTC PINK Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchanges: DPD2


 NR-2017-IME- 6

 
 Imagin Medical 
Closes Private Placement of Convertible Notes

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care
---> for urologists in detecting cancers and visualizing the surgical field during minimally invasive surgeries. The Compa
--->ny's initial focus is bladder cancer.


Vancouver, B.C. and Boston, MA, March 3, 2017 - Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock
---> Exchanges: DPD2) (the "Company") announced today that it has closed the private placement announced on February 24, 2
--->017 through the issuance of Cdn$118,000 aggregate principal amount unsecured convertible notes (the "Notes") at a pric
--->e of $1,000 of principal amount per Note.

The Notes provide the following terms:

(i)   Each Note shall be for a term of 12 months from the date of Closing (subject to the prepayment and conversion te
--->rms hereinafter set forth);

(ii)  The Notes will bear interest from the date of Closing at the rate of 10.0% per annum calculated annually and pay
--->able on maturity;

(iii) The subscribers may at any time following the date of Closing elect to convert any portion of the Note, plus acc
--->rued interest to the date of conversion, into Units of the Issuer at the conversion price of $0.09 per Unit; each Unit
---> consisting of one share and one warrant exercisable for 12 months at $0.12 per share

(iv) At maturity, all unpaid principal and interest under the Notes shall be repaid in full, at the election of the Is
--->suer, either:
(a)   in cash;
(b)   in Units priced at $0.09 per Unit; or 
(c)   any combination thereof.

The Company's president and two directors (the insiders) invested a total of $61,000 in this financing.  
No Finder's fees were paid in this financing.  The Company will be making applicable filings with the CSE.  

Proceeds from the placement will be used for general working capital purposes, including advancing the development of 
--->imaging solutions for the early detection of cancer through the use of endoscopes.

About Imagin Medical  
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Co
--->mpany believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder c
--->ancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a gr
--->eater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive
---> imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical
--->.com.

ON BEHALF OF THE BOARD:
 
Jim Hutchens,
President & CEO
For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com

CAUTIONARY DISCLAIMER STATEMENT:  The Canadian Securities Exchange has not reviewed and does not accept responsibility
---> for the adequacy or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements. These statements reflect management's 
--->current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company ca
--->utions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a n
--->umber of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, cond
--->itions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied
---> in the forward looking information. Except as required under applicable securities legislation, the Company undertake
--->s no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved
---> the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release
--->. 


File: Imagin - News Release - Private Placement Closes - FINAL.pdf

                                                                                                133 Hampshire Road
890 West Pender Street, Suite 600
                                                                                                Wellesley, MA, 02481, 
--->USA
Vancouver, British Columbia
                                                                                                617-571-6006
Canada V6C 1J9
                                                                                                www.imaginmedical.com
778-998-5000


      CSE Symbol: IME                                                                         NR-2017-IME- 6
      OTC PINK Symbol: IMEXF
      Frankfurt/Stuttgart Stock Exchanges: DPD2


                                                    Imagin Medical
                                    Closes Private Placement of Convertible Notes

      Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish
      a new standard of care for urologists in detecting cancers and visualizing the surgical field
      during minimally invasive surgeries. The Company's initial focus is bladder cancer.


      Vancouver, B.C. and Boston, MA, March 3, 2017   Imagin Medical (CSE: IME) (OTC PINK:
      IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the "Company") announced today that
      it has closed the private placement announced on February 24, 2017 through the issuance of
      Cdn$118,000 aggregate principal amount unsecured convertible notes (the "Notes") at a price
      of $1,000 of principal amount per Note.

      The Notes provide the following terms:

             (i)       Each Note shall be for a term of 12 months from the date of Closing (subject to the
                      prepayment and conversion terms hereinafter set forth);

             (ii)     The Notes will bear interest from the date of Closing at the rate of 10.0% per annum
                      calculated annually and payable on maturity;

             (iii)    The subscribers may at any time following the date of Closing elect to convert any
                      portion of the Note, plus accrued interest to the date of conversion, into Units of the
                      Issuer at the conversion price of $0.09 per Unit; each Unit consisting of one share
                      and one warrant exercisable for 12 months at $0.12 per share

             (iv)     At maturity, all unpaid principal and interest under the Notes shall be repaid in full,
                      at the election of the Issuer, either:
                       (a) in cash;
                       (b) in Units priced at $0.09 per Unit; or
                       (c) any combination thereof.

      The Company's president and two directors (the insiders) invested a total of $61,000 in this
      financing.

      No Finder's fees were paid in this financing. The Company will be making applicable filings
      with the CSE.

      Proceeds from the placement will be used for general working capital purposes, including
      advancing the development of imaging solutions for the early detection of cancer through the
      use of endoscopes.

      {00685280;1}
 About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the
use of endoscopes. The Company believes it will radically improve the way physicians detect
cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth
most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50%
recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced,
ultrasensitive imaging technology is based upon improved optical designs and advanced light
sensors. Learn more at www.imaginmedical.com.


ON BEHALF OF THE BOARD:

Jim Hutchens,
President & CEO
For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements. These statements reflect management's
current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company
cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a
number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events,
conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or imp
--->lied
in the forward looking information. Except as required under applicable securities legislation, the Company undertakes
---> no
obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the
information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.




{00685280;1}